Q&A: FDA's Peter Marks ready to encourage more accelerated approvals for rare diseases

Lia DeGroot

FDA biologics center director Peter Marks said the agency plans to encourage sponsors to use the accelerated approval pathway, particularly for rare disease treatments, as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Q&A: FDA's Peter Marks ready to encourage more accelerated approvals for rare diseases

Lia DeGroot

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Q&A: FDA's Pe­ter Marks ready to en­cour­age more ac­cel­er­at­ed ap­provals for rare dis­eases

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Q&A: FDA's Peter Marks ready to encourage more accelerated approvals for rare diseases